AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3317337 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 26
Study 3317337 — intervention group
Group type: COMPARATOR
Intervention: Combination of both drugs
Number of subjects: 26
Study 29420951 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (subconjunctival injection)
Number of subjects: 213
Study 29420951 — intervention group
Group type: COMPARATOR
Intervention: Standard group (control)
Number of subjects: 213
Study 26660000 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (DL) for de-epithelialization of free gingival graft (FGG) and palatal wound irradiation
Number of subjects: 52
Study 26660000 — intervention group
Group type: COMPARATOR
Intervention: Control group: De-epithelialized gingival grafts (DGG) using blade (DGG-B)
Number of subjects: 52
Study 26660000 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (DGG-L and DGG-B)
Number of subjects: 52
Study 24907185 — intervention group
Group type: COMPARATOR
Intervention: 120 kVp protocol
Number of subjects: 157
Study 24907185 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kVp protocol
Number of subjects: 157
Study 24907185 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 kVp protocol
Number of subjects: 157
Study 22901422 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily pin site care
Number of subjects: 56
Study 22901422 — intervention group
Group type: COMPARATOR
Intervention: No pin tract care
Number of subjects: 56
Study 20339195 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic left ventricular hypertrophy (LVH) measured by SV1+ RV5
Number of subjects: 3230
Study 20339195 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic left ventricular hypertrophy (LVH) classified at threshold values of 35 mm
Number of subjects: 3230
Study 20339195 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic left ventricular hypertrophy (LVH) classified at threshold values of 40 mm
Number of subjects: 3230
Study 20339195 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing SV1+ RV5 values
Number of subjects: 3230
Study 18417560 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory ergonomics intervention (n = 59)
Number of subjects: 504
Study 18417560 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 60)
Number of subjects: 504
Study 15882256 — intervention group
Group type: EXPERIMENTAL
Intervention: AT1R blocker (losartan)
Number of subjects: 21
Study 15882256 — intervention group
Group type: EXPERIMENTAL
Intervention: AT1R blocker (candesartan)
Number of subjects: 21
Study 15882256 — intervention group
Group type: EXPERIMENTAL
Intervention: AT1R blocker treatment
Number of subjects: 21
Study 11788564 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy (10 Gy)
Number of subjects: 22
Study 11788564 — intervention group
Group type: COMPARATOR
Intervention: Control (no further therapy)
Number of subjects: 22
Study 10411764 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 100
Study 10411764 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 100
Study 10411764 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam premedication
Number of subjects: 100
Study 10411764 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with no premedication
Number of subjects: 100
Study 10411764 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam preoperatively with sevoflurane
Number of subjects: 100
Study 7586401 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade/retrograde cold blood cardioplegia (CBP, 23 patients)
Number of subjects: 64
Study 7586401 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade crystalloid cardioplegia (CCP, 21 patients)
Number of subjects: 64
Study 7586401 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous retrograde warm blood cardioplegia (WBP, 20 patients)
Number of subjects: 64
Study 2405271 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection of brain metastases followed by radiotherapy
Number of subjects: 48
Study 2405271 — intervention group
Group type: COMPARATOR
Intervention: Needle biopsy and radiotherapy
Number of subjects: 48
Study 352634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidoflazine
Number of subjects: 21
Study 352634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 30968546 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO PCI
Number of subjects: 302
Study 30968546 — intervention group
Group type: COMPARATOR
Intervention: no-CTO PCI
Number of subjects: 302
Study 30968546 — intervention group
Group type: EXPERIMENTAL
Intervention: successful CTO PCI
Number of subjects: 302
Study 30968546 — intervention group
Group type: COMPARATOR
Intervention: failed/no-CTO PCI
Number of subjects: 302
Study 28077221 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy (BT)
Number of subjects: 47
Study 28077221 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Therapy (CT)
Number of subjects: 47
Study 28077221 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 47
Study 25851802 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (80 mg for 15-40 kg, 125 mg for 41-65 kg on day 1, 80 mg for days 2-3)
Number of subjects: 93
Study 25851802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 23910768 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular fat meal
Number of subjects: 191
Study 23910768 — intervention group
Group type: COMPARATOR
Intervention: High fat meal
Number of subjects: 191
Study 23910768 — intervention group
Group type: EXPERIMENTAL
Intervention: Large meal
Number of subjects: 191
Study 23910768 — intervention group
Group type: COMPARATOR
Intervention: Small meal
Number of subjects: 191
Study 23910768 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived similarity to the target
Number of subjects: 191
Study 23910768 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem
Number of subjects: 191
Study 21528603 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point‐sticking group (APS group, n=31)
Number of subjects: 92
Study 21528603 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n=31)
Number of subjects: 92
Study 21528603 — intervention group
Group type: COMPARATOR
Intervention: Blank group (n=30)
Number of subjects: 92
Study 19267731 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based advanced symptom management system (ASyMS)
Number of subjects: 112
Study 19267731 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 112
Study 17026492 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg/day for 12 weeks
Number of subjects: 195
Study 17026492 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 195
Study 15126259 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiography alone or in combination with sputum cytologic examination
Number of subjects: 0
Study 15126259 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (CT)
Number of subjects: 0
Study 15126259 — intervention group
Group type: COMPARATOR
Intervention: Control group (unspecified screening methods)
Number of subjects: 0
Study 15126259 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-control studies from Japan
Number of subjects: 0
Study 15126259 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening methods (general)
Number of subjects: 0
Study 11404278 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (total dose of 256 g)
Number of subjects: 9
Study 11404278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9248820 — intervention group
Group type: EXPERIMENTAL
Intervention: Number-consonant mnemonic training (n = 17)
Number of subjects: 36
Study 9248820 — intervention group
Group type: COMPARATOR
Intervention: Placebo training (n = 19)
Number of subjects: 36
Study 8485531 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (D1) of Tacrine (40 mg/day)
Number of subjects: 0
Study 8485531 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (D2) of Tacrine (80 mg/day)
Number of subjects: 0
Study 8485531 — intervention group
Group type: COMPARATOR
Intervention: Placebo (D0)
Number of subjects: 0
Study 3315265 — intervention group
Group type: EXPERIMENTAL
Intervention: Euphyllin CR (642 mg total daily dose, 1/3 in the morning and 2/3 in the evening, evening dose at 2200 hr)
Number of subjects: 20
Study 3315265 — intervention group
Group type: EXPERIMENTAL
Intervention: Afonilum Retard (500 mg total daily dose, equal amounts in the morning and evening, evening dose at 2000 hr)
Number of subjects: 20
Study 3315265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29036504 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone/amiloride or losartan
Number of subjects: 110
Study 27422692 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB) - 20 mL bupivacaine/20 mL saline, intraoperative local infiltration
Number of subjects: 57
Study 27422692 — intervention group
Group type: COMPARATOR
Intervention: Interscalene nerve block (INB), preoperative
Number of subjects: 57
Study 27422692 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LB and INB
Number of subjects: 57
Study 24473100 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop control (fMRI activity in SPL and cerebellum)
Number of subjects: 0
Study 24473100 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-loop control (fMRI activity in IPL and prefrontal areas)
Number of subjects: 0
Study 24473100 — intervention group
Group type: EXPERIMENTAL
Intervention: Aiming movements with a stick
Number of subjects: 0
Study 24473100 — intervention group
Group type: COMPARATOR
Intervention: Aiming movements with a laser pointer
Number of subjects: 0
Study 23584651 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost (0.03 %)
Number of subjects: 31
Study 23584651 — intervention group
Group type: COMPARATOR
Intervention: Travoprost (0.004 %)
Number of subjects: 31
Study 23584651 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 31
Study 20683094 — intervention group
Group type: EXPERIMENTAL
Intervention: Message tailored to physical activity as an expert-determined topic (expert)
Number of subjects: 408
Study 20683094 — intervention group
Group type: COMPARATOR
Intervention: Message tailored to physical activity as a participant-selected topic (choice)
Number of subjects: 408
Study 20683094 — intervention group
Group type: COMPARATOR
Intervention: Nontailored message (comparison)
Number of subjects: 408
Study 18000088 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 312
Study 16184062 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 mg/kg midazolam
Number of subjects: 100
Study 16184062 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg midazolam
Number of subjects: 100
Study 16184062 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg midazolam
Number of subjects: 100
Study 16184062 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study 16184062 — intervention group
Group type: COMPARATOR
Intervention: Group A (placebo)
Number of subjects: 100
Study 16184062 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (1.0 mg/kg midazolam)
Number of subjects: 100
Study 12626890 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor (PI) users
Number of subjects: 1785
Study 12626890 — intervention group
Group type: COMPARATOR
Intervention: Reverse transcriptase inhibitor (RTI) users
Number of subjects: 1785
Study 12626890 — intervention group
Group type: COMPARATOR
Intervention: No antiretroviral therapy (ART) users
Number of subjects: 1785
Study 12626890 — intervention group
Group type: COMPARATOR
Intervention: HIV-uninfected women
Number of subjects: 1785
Study 12626890 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1785
Study 12626890 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1785
Study 10384925 — intervention group
Group type: EXPERIMENTAL
Intervention: Scrubbing up with a brush
Number of subjects: 0
Study 10384925 — intervention group
Group type: COMPARATOR
Intervention: Simple hand washing without a brush
Number of subjects: 0
Study 9295498 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-agent controlling method to promote milk secretion
Number of subjects: 280
Study 9295498 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 280
Study 1852848 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive treatment program (parent training and training of boys for social skills, fantasy play, and television viewing)
Number of subjects: 0
Study 1852848 — intervention group
Group type: COMPARATOR
Intervention: Nontreated group 1
Number of subjects: 0
Study 1852848 — intervention group
Group type: COMPARATOR
Intervention: Nontreated group 2
Number of subjects: 0
Study 6660455 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone anesthesia
Number of subjects: 39
Study 6660455 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone anesthesia
Number of subjects: 39
Study 6660455 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonoperated patients)
Number of subjects: 39
Study 30704862 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS treatment
Number of subjects: 26
Study 30704862 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS treatment
Number of subjects: 26
Study 28382811 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient NIV initiation
Number of subjects: 50
Study 28382811 — intervention group
Group type: COMPARATOR
Intervention: Inpatient NIV initiation
Number of subjects: 50
Study 28382811 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV acceptance (>4 h/night)
Number of subjects: 50
Study 28382811 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV adherence (>120 h/month)
Number of subjects: 50
Study 25826334 — intervention group
Group type: EXPERIMENTAL
Intervention: 25g glucose drink
Number of subjects: 67
Study 25826334 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo drink
Number of subjects: 67
Study 25826334 — intervention group
Group type: EXPERIMENTAL
Intervention: High motivation
Number of subjects: 67
Study 25826334 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of self‐control
Number of subjects: 67
Study 21296248 — intervention group
Group type: EXPERIMENTAL
Intervention: IV paracetamol 15 mg/kg
Number of subjects: 64
Study 21296248 — intervention group
Group type: COMPARATOR
Intervention: IV tramadol 1.0 mg/kg
Number of subjects: 64
Study 19577902 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal packing with septal splints and antibiotic meshes
Number of subjects: 114
Study 19577902 — intervention group
Group type: COMPARATOR
Intervention: Trans-septum suturing without packing
Number of subjects: 114
Study 17074346 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral E(2) (oE(2), 1 mg/d)
Number of subjects: 50
Study 17074346 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E(2) (tE(2), 0.05 mg/d)
Number of subjects: 50
Study 15238023 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture encoding
Number of subjects: 0
Study 15238023 — intervention group
Group type: COMPARATOR
Intervention: Word encoding
Number of subjects: 0
Study 15238023 — intervention group
Group type: EXPERIMENTAL
Intervention: Postrecall recognition test
Number of subjects: 0
Study 11555457 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial features assessed by transvaginal ultrasound
Number of subjects: 145
Study 11555457 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial growth and its pattern transformation during stimulation
Number of subjects: 145
Study 9594760 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:50,000 epinephrine
Number of subjects: 30
Study 9594760 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:80,000 epinephrine
Number of subjects: 30
Study 9594760 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 30
Study 9594760 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral canine)
Number of subjects: 30
Study 7950108 — intervention group
Group type: EXPERIMENTAL
Intervention: No-stitch technique
Number of subjects: 300
Study 7950108 — intervention group
Group type: COMPARATOR
Intervention: Sutured scleral wound closure
Number of subjects: 300
Study 3661439 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg once or twice daily for 6 weeks
Number of subjects: 32
Study 3661439 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg plus amiloride 2.5 mg once or twice daily for 6 weeks
Number of subjects: 32
Study 3661439 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg plus hydrochlorothiazide 25 mg and amiloride 2.5 mg
Number of subjects: 32
Study 3661439 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine for an additional period of 6 months
Number of subjects: 32
Study 3661439 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low-dose nisoldipine and low-dose diuretic
Number of subjects: 32
Study 30346497 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced self-regulation condition (writing about stress and coping at week 1, deepest feelings at week 2, and finding benefits at week 3)
Number of subjects: 136
Study 30346497 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation condition (writing about deepest feelings at week 1, stress and coping at week 2, and finding benefits at week 3)
Number of subjects: 136
Study 30346497 — intervention group
Group type: COMPARATOR
Intervention: Cancer-fact condition (writing about facts relevant to the cancer experience for three weeks)
Number of subjects: 136
Study 28103616 — intervention group
Group type: EXPERIMENTAL
Intervention: l-Lysine (4.95 g/day orally)
Number of subjects: 20
Study 28103616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25742208 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 25 mg daily plus 25 mg targeted (at most daily) in anticipation of drinking
Number of subjects: 128
Study 25742208 — intervention group
Group type: COMPARATOR
Intervention: Daily/targeted placebo
Number of subjects: 128
Study 24304689 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist medical care plus the Lightning Process (LP)
Number of subjects: 56
Study 24304689 — intervention group
Group type: COMPARATOR
Intervention: Specialist medical care
Number of subjects: 56
Study 21234852 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (Cor, 50 mg/day for 7 days)
Number of subjects: 9
Study 21234852 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 9
Study 18259123 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg (titrated to 100 mg/d at 4 weeks)
Number of subjects: 36
Study 18259123 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol succinate 50 mg (titrated to 100 mg/d at 4 weeks)
Number of subjects: 36
Study 16907691 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 2
Study 16907691 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study 16907691 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept treatment (efficacy data from RCT)
Number of subjects: 2
Study 16907691 — intervention group
Group type: COMPARATOR
Intervention: Control group (efficacy data from RCT)
Number of subjects: 2
Study 14570732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis based on rectal sensitivity and psychological symptoms
Number of subjects: 107
Study 14570732 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial factors included in analysis
Number of subjects: 107
Study 11105477 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for lie detection; 2 days of training, with assessments before and after training.
Number of subjects: 32
Study 11105477 — intervention group
Group type: COMPARATOR
Intervention: Feedback group; received feedback on accuracy after each judgment.
Number of subjects: 32
Study 11105477 — intervention group
Group type: COMPARATOR
Intervention: Feedback + cue information group; received feedback and information on cues to deception.
Number of subjects: 32
Study 9187779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (ITF) 25 micrograms
Number of subjects: 24
Study 9187779 — intervention group
Group type: COMPARATOR
Intervention: Lumbar epidural analgesia (LEA) with epidural lidocaine 1.5%
Number of subjects: 24
Study 1347230 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.6 mg kg‐1
Number of subjects: 16
Study 1347230 — intervention group
Group type: COMPARATOR
Intervention: H1- and H2-receptor antagonists + Atracurium 0.6 mg kg‐1
Number of subjects: 16
Study 4007349 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin therapy (Group A)
Number of subjects: 24
Study 4007349 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Group B)
Number of subjects: 24
Study 31744458 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA-a)
Number of subjects: 0
Study 31744458 — intervention group
Group type: COMPARATOR
Intervention: Erythropoietin (EPO)
Number of subjects: 0
Study 29193767 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (EMPA)
Number of subjects: 109
Study 29193767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 27401884 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention program (nine lessons, 45 mins per week for 9 weeks)
Number of subjects: 3000
Study 27401884 — intervention group
Group type: COMPARATOR
Intervention: Standard relaxation program (Relax)
Number of subjects: 3000
Study 27401884 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment control group
Number of subjects: 3000
Study 24678758 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive mobilization and stretching
Number of subjects: 9
Study 24678758 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual orthopaedic therapy with proprioception training
Number of subjects: 9
Study 22354999 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-instruction for CFS delivered by nurses
Number of subjects: 123
Study 22354999 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 123